Strain EC, Bigelow GE, Liebson IA, Stitzer ML. 1999. Moderate- vs high-done methadone in the treatment of opioid dependence: A randomized trial. Journal of the American Medical Association. 281(11):1000–1005.

Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M, Stewart D, Welch S. 2000. Randomized trial of supervised injectable versus oral methadone maintenance: Report of feasibility and 6-month outcome. Addiction. 95(11):1631–1645.

Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M. 2003. Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. British Medical Journal. 326:959–960.

Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. 2006. The status of Disulfiram: A half century later. Journal of Clinical Psychopharmacology. 26(3):290–302.

Tennant FS, Rawson RA, Cohen AJ, Mann A. 1984. Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry. 45(9 pt 2):42–45.

Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. 2005. Prediction of relapse to frequent heroin use and the role of methadone prescription: An analysis of the Amsterdam Cohort Study among drug users. Drug and Alcohol Dependence. 79(2):231–240.

Thiede H, Hagan H, Murrill CS. 2000. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health. 77(3): 331–345.

Turner BJ, Laine C, Yang CP, Hauck WW. 2003. Effects of long-term, medically supervised, drug-free treatment and methadone maintenance treatment on drug users’ emergency department use and hospitalization. Clinical Infectious Diseases. 37(Suppl 5):S457.

U.S. FDA (Food and Drug Administration). 2001, March. Index of Safety-Related Drug Labeling Changes Summaries Approved by the FDA Center for Drug Evaluation and Research (CDER). Medwatch. [Online]. Available: http://www.fda.gov/medwatch/safety/2001/mar01.htm [accessed June 30, 2006].

van Ameijden EJ, Langendam MW, Coutinho RA. 1999. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addictive Behaviors. 24(4):559–563.

Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. 1991. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: Implications for prevention of HIV. International Journal of Addictions. 26(12):1313–1320.

Varescon I, Vidal-Trecan G, Nabet N, Boissonnas A. 2002. Buprenorphine abuse: High dose intravenous administration of buprenorphine. L’Encéphale. 5(Pt 1):397–402.

Vocci FJ, Elkashef A. 2005. Pharmacotherapy and other treatments for cocaine abuse and dependence. Current Opinion in Psychiatry. 18:265–270.

Washton AM, Pottash AC, Gold MS. 1984. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry. 45(9 pt 2):39–41.

WHO (World Health Organization), United Nations Office on Drugs and Crime, and Joint United Nations Programme on HIV/AIDS. 2004. Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention: Position Paper. Geneva, Switzerland: WHO.

Williams AB, McNelly EA, Williams AE, D’Aquila RT. 1992. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care. 4(1): 35–41.

Williamson PA, Foreman KJ, White JM, Anderson G. 1997. Methadone-related overdose deaths in South Australia 1984–1994. Medical Journal of Australia. 166: 302–305.

Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, Robinson JW. 1991. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health. 81(9):1185–1191.